Australia & South Korea Diabetic Foot Ulcer Market to Grow at a CAGR of 5.8% to reach US$ 313.53 billion from 2022 to 2030
The Australia & South Korea diabetic foot ulcer market size was valued at US$ 199.59 billion in 2022 and is projected to reach US$ 313.53 billion by 2030; it is estimated to register a CAGR of 5.8% from 2022 to 2030.
Market Insights and Analyst View:
Diabetic foot ulcers are the most common complications that occur in patients suffering from diabetes mellitus, wherein the condition is not well controlled. The ulcer develops within a callosity on a pressure site and is often painless, leading to a delay in diagnosis, as well as treatment. The open sore or wound usually occurs in approximately 15% of patients with diabetes. Diabetic foot ulcers can also affect patients who have diabetes-related kidney, skin, or heart disease; patients who are obese; and those who consume alcohol in high risk volumes. High prevalence of diabetes and related chronic wounds, and a surge in the geriatric population are driving the Australia & South Korea diabetic foot ulcer market. However, the high cost of advanced wound care treatments hinders the Australia & South Korea diabetic foot ulcer market growth.
Growth Drivers and Challenges:
Diabetic patients are vulnerable to wounds, and the healing process is usually longer. Depending on the healing timeframe, wounds are classified as acute and chronic. According to the Australian Institute of Health and Welfare, over 1.3 million (1 in 20) Australians had diabetes in 2021. In South Korea, the prevalence of diabetes is growing, presenting significant challenges to the economy, healthcare system, and society. According to the Korean Diabetes Association, in 2020, the estimated prevalence of diabetes mellitus was 16.7% among the Korean population aged 30 years or older. Blood vessels and nerves in the feet of diabetic patients are prone to damages, resulting in numbness. Due to this, diabetic patients have a higher chance of developing diabetic foot ulceration. According to the National Center for Biotechnology Information (NCBI), nearly 15–25% of diabetic patients can develop a diabetic foot ulcer (DFU) during their lifetime. Due to diabetes, over 4,400 amputations are performed yearly in Australia, which is the second-highest rate in the developed world. According to data released by Diabetes Feet Australia and the Australian Diabetes Society in 2020, ~50,000 Australians develop diabetes-related foot disease (DFD) annually, with a further 300,000 having risk factors for developing DFD. Thus, the demand for diabetic foot ulcer treatments is on the rise in Australia and South Korea.
Age-associated diabetes is common in Australia and South Korea. According to the Australian Institute of Health and Welfare data published in 2021, almost 1 in 5 Australians aged 80–84 years are reported to have diabetes; it is nearly 30 times more frequent in this age group than those under 40 years (0.7%). According to the Statistics Korea report, 8.53 million were aged 65 years and older in 2021. The same report also estimated that the number of older people is likely to account for 43.9% of the country's population by 2050. However, wound care treatments are performed when the injured skin loses its ability to heal, making it an expensive procedure. According to the data published in Diabetes Australia, it is estimated that diabetic foot disease costs Australia ~US$ 875 million annually. Furthermore, a diabetes-associated limb amputation procedure costs nearly US$ 23,555, with an additional annual post-surgery expense of US$ 6,065. Over 5 years, diabetes-related amputation amounted to almost US$ 50,000 for the health system, excluding social costs. The area of a wound and the complexity of procedures also determine the cost of the treatment. Thus, the high cost of advanced wound care treatments, despite the availability of reimbursements, is a key factor restraining the Australia & South Korea diabetic foot ulcer market growth.
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Australia & South Korea Diabetic Foot Ulcer Market: Strategic Insights
Market Size Value in US$ 199.59 billion in 2022 Market Size Value by US$ 313.53 billion by 2030 Growth rate CAGR of 5.8% from 2022 to 2030 Forecast Period 2022-2030 Base Year 2022
Mrinal
Have a question?
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Australia & South Korea Diabetic Foot Ulcer Market: Strategic Insights
| Market Size Value in | US$ 199.59 billion in 2022 |
| Market Size Value by | US$ 313.53 billion by 2030 |
| Growth rate | CAGR of 5.8% from 2022 to 2030 |
| Forecast Period | 2022-2030 |
| Base Year | 2022 |
Mrinal
Have a question?
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
Report Segmentation and Scope:
The “Australia & South Korea Diabetic Foot Ulcer Market” is segmented based on ulcer type, treatment type, infection severity, and end user, and country.
Segmental Analysis:
Based on ulcer type, the Australia & South Korea diabetic foot ulcer market is segmented into neuropathic ulcers, ischemic ulcers, and neuro-ischemic ulcers. The neuro-ischemic ulcers segment held the largest share of the Australia & South Korea diabetic foot ulcer market in 2022, and it is anticipated to register the highest CAGR during the forecast period. Diabetic patients are vulnerable to wounds, and the healing process is usually longer. Neuro-ischemia predominately leads to the development of ulcers on the foot, toes, and dorsum margins, especially on pressure sites occurring among people using poorly fitting shoes. The management of such types of wounds is comparatively complex. The wound requires prompt care, appropriate footwear, offloading, dressings, and infection treatment. However, neuro-ischemic ulcers are the most common diabetic foot ulcers. The neuro-ischemic ulcers are caused in patients with peripheral neuropathy and ischemia, resulting in peripheral artery disease. The treatment of neuro-ischemic ulcers includes referral, debridement, footwear modifications, and infection treatment through vascular surgeries and suitable drugs such as antibiotics. In addition, the wound needs to be kept clean regularly, and the blood sugar levels must be within limits to avoid any possible complications.
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
The Australia & South Korea diabetic foot ulcer market, by treatment type, is segmented into advanced wound care dressings, biologics, and therapy device. The advanced wound care dressings segment held the largest share of Australia & South Korea diabetic foot ulcer market in 2022. The biologics segment is anticipated to register the highest CAGR of 6.4% during 2022–2030.
Only standard-of-care therapy is often not sufficient to heal diabetic foot ulcer wounds and requires the subsequent or simultaneous application of adjuvant wound therapies, including biological skin substitutes. Biologics are developed from natural sources, including humans, animals, and microorganisms. Cell-based biological substitutes are used particularly for the treatment of wounds.
Regional Analysis:
Based on country, the Australia & South Korea diabetic foot ulcer market is divided Australia and South Korea. South Korea held a larger market share owing to the growing cases of diabetes. Diabetes is a significant public health issue nationwide, and its burden is projected to increase in the coming years. According to a study titled Plantar Forefoot Reconstruction in Diabetic Foot Ulcers: A Comparative Study of Perforator Valves and Accidental Valves, published in the Journal of Wound Management and Research in South Korea, in 2021, the number of patients suffering from diabetes mellitus foot problems rose to ~1.4% of the total population, with 0.4% of the total population appearing each year. According to the results of the National Health and Nutrition Survey 2012–2018, 1 in 7 persons over 30 years of age, i.e., 13.8% of South Korea's adult population, has diabetes. The older the age, the higher the prevalence of diabetes. In South Korea, the prevalence of diabetes in men in their 40s and women in their 50s is over 10%. It is estimated that 15–25% of people with diabetes will develop a foot ulcer at some point, with more than half having other complications related to the infection. In extreme cases, ~20% of moderate to severe infections require a foot amputation. Therefore, the number of diabetic patients is also expected to increase with the rising geriatric population, which, in turn, will drive the growth of the diabetic foot ulcer market in South Korea.
Increasing collaborations between public and private players are also driving the growth of the Australia & South Africa foot ulcer treatment market. Lescarden Inc. entered into a license agreement with Daewoong Pharmaceutical Co., Ltd. (Seoul, South Korea), granting Daewoong a 10-year exclusive license to market Catrix(R) diabetic foot ulcer wound dressing in South Korea. Catrix (R) wound dressing, its proprietary product, is a biologic compound derived from specially processed bovine cartilage. The FDA and the EU have approved this compound for managing diabetic foot ulcers. In February 2019, ROKIT Healthcare, a South Korea-based medical startup, came up with a radical regenerative solution for treating diabetic foot ulcers by using a proprietary three-dimensional bioprinting strategy. Further, in September 2021, Rokit Healthcare Inc. received approval from the South Korean Ministry of Food and Drug Safety (MFDS) for Dfurege—an artificial organ platform for treating diabetic foot ulcers.
Therefore, growing geriatric population, increasing diabetes cases, and surging collaborations and product approvals boost the diabetic foot ulcer market in South Korea.
Competitive Landscape and Key Companies:
Developments in the Australia & South Korea diabetic foot ulcer market have been characterized as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as launches, expansion, enhancement, and relocation. Inorganic growth strategies witnessed in the Australia & South Korea diabetic foot ulcer market were mergers & acquisitions, partnership, and collaborations. These activities have paved the way for the expansion of business and customer base of Australia & South Korea diabetic foot ulcer market players.
- In January 2023, MiMedx Group, Inc. entered into an exclusive distribution agreement with GUNZE MEDICAL LIMITED (“Gunze Medical”), a subsidiary of Gunze Limited, for sales of EPIFIX in Japan. Gunze Medical is a leading distributor of products used in a wide range of wound and surgical settings, including bioabsorbable devices and materials, such as sutures and sheet products.
- In August 2021, URGO Medical partnered with Diabetes Feet Australia (DFA). As part of their charter, DFA has been working on developing evidence-based guidelines for the Australian healthcare sector for diabetes-related foot disease, which would serve as the new national multi-disciplinary best practice standards of care for providing diabetic foot disease care within Australia.
- In October 2019, 3M acquired Acelity, Inc. and its KCI subsidiaries worldwide. Acelity is a globally leading medical technology company that focuses on offering advanced wound care and specialty surgical solutions under its KCI brand. This acquisition has further accelerated 3M's position as a leader in the advanced wound care market.
- In April 2023, 3M Health Care received Food and Drug Administration (FDA) clearance for its innovative 3M Veraflo Therapy, comprising 3M Veraflo Cleanse Choice Complete Dressing and 3M V.A.C. Veraflo Cleanse Choice Dressing, which facilitates hydromechanical removal of infectious materials, non-viable tissue, and wound debris. The product also reduces the number of surgical debridement’s required, while promoting granulation tissue formation and creating an environment that promotes wound healing.
- In July 2022, Smith+Nephew launched the WOUND COMPASS Clinical Support App. It is a comprehensive digital support tool for healthcare professionals that aids wound assessment and decision-making to help reduce practice variation. The App helps improve nurse confidence when assessing and treating wounds and reassuring specialist nurses that their formulary is followed.
- In March 2022, Convatec entered the attractive wound biologics segment by acquiring Triad Life Sciences Inc. The company develops biologically derived innovative products to address unmet clinical needs associated with surgical wounds, chronic wounds, and burns.
Company Profiles
- MiMedx Group, Inc
- Convatec Group Plc
- URGO MEDICAL Australia Pty Ltd
- 3M
- Organogenesis Inc.
- Smith+Nephew
- Coloplast AS
- B. Braun SE
- Molnlycke Health Care AB
- Medline Industries LP
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
Ulcer Type, Treatment Type, Infection Severity, End User, and Country
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
1. Introduction
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Australia & South Korea Diabetic Foot Ulcer Market – Market Landscape
4.1 Overview
4.1.1 Australia & South Korea PEST Analysis
4.2 Ecosystem Analysis
4.3 Classification Systems of Diabetic Foot Ulcer
4.3.1 SINBAD (Site, Ischemia, Neuropathy, Bacterial infection, Depth)
4.3.2 PEDIS (Perfusion, Extent, Depth, Infection, Sensation)
4.3.3 UT (University of Texas)
4.3.4 WIFI (Wound, Ischemia, and Foot Infection)
4.3.5 Meggitt-Wagner System
4.3.6 Others
4.4 Australian Guidelines on Wound Classification of Diabetes-Related Foot Ulcers
4.4.1 Overview
4.5 Number of Hospitalizations for DFU in Australia and South Korea, 2022
5. Australia & South Korea Diabetic Foot Ulcer Market – Country Analysis
5.1 Key Market Drivers:
5.1.1 High Prevalence of Diabetes and Related Chronic Wounds
5.1.2 Surge in Geriatric Population
5.2 Market Restraints
5.2.1 High Cost of Advanced Wound Care Treatments
5.3 Market Opportunities
5.3.1 Growing Research Activities to Unveil Novel Wound Treatment Products
5.4 Future Trends
5.4.1 Use of 3D Printing in Wound Care Management
5.5 Impact Analysis:
6. Australia & South Korea Diabetic Foot Ulcer Market – Country Analysis
6.1 Australia & South Korea Diabetic Foot Ulcer Market Revenue Forecast and Analysis
7. Australia & South Korea Diabetic Foot Ulcer Market – Revenue and Forecast to 2030 – by Treatment Type
7.1 Overview
7.2 Australia & South Korea Diabetic Foot Ulcer Market Revenue Share, by Treatment Type 2022 & 2030 (%)
7.3 Advanced Wound Care Dressings
7.3.1 Overview
7.3.2 Advanced Wound Care Dressings: Australia & South Korea Diabetic Foot Ulcer Market – Revenue and Forecast to 2030 (US$ Million)
7.3.3 Alginate Dressings
7.3.3.1 Overview
7.3.3.2 Alginate Dressings: Australia & South Korea Diabetic Foot Ulcer Market – Revenue and Forecast to 2030 (US$ Million)
7.3.4 Hydrofiber Dressings
7.3.4.1 Overview
7.3.4.2 Hydrofiber Dressings: Australia & South Korea Diabetic Foot Ulcer Market – Revenue and Forecast to 2030 (US$ Million)
7.3.5 Foam Dressings
7.3.5.1 Overview
7.3.5.2 Foam Dressings: Australia & South Korea Diabetic Foot Ulcer Market – Revenue and Forecast to 2030 (US$ Million)
7.3.6 Collagen Dressing
7.3.6.1 Overview
7.3.6.2 Collagen Dressing: Australia & South Korea Diabetic Foot Ulcer Market – Revenue and Forecast to 2030 (US$ Million)
7.3.7 Film Dressing
7.3.7.1 Overview
7.3.7.2 Film Dressing: Australia & South Korea Diabetic Foot Ulcer Market – Revenue and Forecast to 2030 (US$ Million)
7.3.8 Other Dressings
7.3.8.1 Overview
7.3.8.2 Other Dressing: Australia & South Korea Diabetic Foot Ulcer Market – Revenue and Forecast to 2030 (US$ Million)
7.4 Biologics
7.4.1 Overview
7.4.2 Biologics: Australia & South Korea Diabetic Foot Ulcer Market – Revenue and Forecast to 2030 (US$ Million)
7.4.3 Growth Factors
7.4.3.1 Overview
7.4.3.2 Growth Factors: Australia & South Korea Diabetic Foot Ulcer Market – Revenue and Forecast to 2030 (US$ Million)
7.4.4 Skin Graft
7.4.4.1 Overview
7.4.4.2 Skin Graft: Australia & South Korea Diabetic Foot Ulcer Market – Revenue and Forecast to 2030 (US$ Million)
7.5 Therapy Device
7.5.1 Overview
7.5.2 Therapy Device: Australia & South Korea Diabetic Foot Ulcer Market – Revenue and Forecast to 2030 (US$ Million)
7.5.3 Negative Pressure Wound Therapy
7.5.3.1 Overview
7.5.3.2 Negative Pressure Wound Therapy: Australia & South Korea Diabetic Foot Ulcer Market – Revenue and Forecast to 2030 (US$ Million)
7.5.4 Ultrasound Therapy
7.5.4.1 Overview
7.5.4.2 Ultrasound Therapy: Australia & South Korea Diabetic Foot Ulcer Market – Revenue and Forecast to 2030 (US$ Million)
8. Australia & South Korea Diabetic Foot Ulcer Market – Revenue and Forecast to 2030 – By Ulcer Type
8.1 Overview
8.2 Australia & South Korea Diabetic Foot Ulcer Market Revenue Share, By Ulcer Type 2022 & 2030 (%)
8.3 Neuropathic Ulcers
8.3.1 Overview
8.3.2 Neuropathic Ulcers: Australia & South Korea Diabetic Foot Ulcer Market – Revenue and Forecast to 2030 (US$ Million)
8.4 Ischemic Ulcers
8.4.1 Overview
8.4.2 Ischemic Ulcers: Australia & South Korea Diabetic Foot Ulcer Market – Revenue and Forecast to 2030 (US$ Million)
8.5 Neuro-ischemic Ulcers
8.5.1 Overview
8.5.2 Neuro-ischemic Ulcers: Australia & South Korea Diabetic Foot Ulcer Market – Revenue and Forecast to 2030 (US$ Million)
9. Australia & South Korea Diabetic Foot Ulcer Market – Revenue and Forecast to 2030 – By Infection Severity
9.1 Overview
9.2 Australia & South Korea Diabetic Foot Ulcer Market Revenue Share, By Infection Severity 2022 & 2030 (%)
9.3 Mild, Moderate, and Severe
9.3.1 Overview
9.3.2 Mild: Australia & South Korea Diabetic Foot Ulcer Market – Revenue and Forecast to 2030 (US$ Million)
9.3.3 Moderate: Australia & South Korea Diabetic Foot Ulcer Market – Revenue and Forecast to 2030 (US$ Million)
9.3.4 Severe: Australia & South Korea Diabetic Foot Ulcer Market – Revenue and Forecast to 2030 (US$ Million)
10. Australia & South Korea Diabetic Foot Ulcer Market – Revenue and Forecast to 2030 – By End User
10.1 Overview
10.2 Australia & South Korea Diabetic Foot Ulcer Market Revenue Share, By End User 2022 & 2030 (%)
10.3 Hospitals
10.3.1 Overview
10.3.2 Hospitals: Australia & South Korea Diabetic Foot Ulcer Market – Revenue and Forecast to 2030 (US$ Million)
10.4 Ambulatory Surgical Centers
10.4.1 Overview
10.4.2 Ambulatory Surgical Centers: Australia & South Korea Diabetic Foot Ulcer Market – Revenue and Forecast to 2030 (US$ Million)
10.5 Home Care
10.5.1 Overview
10.5.2 Home Care: Australia & South Korea Diabetic Foot Ulcer Market – Revenue and Forecast to 2030 (US$ Million)
11. Australia & South Korea Diabetic Foot Ulcer Market – Revenue and Forecast to 2030 – Geographic Analysis
11.1 Australia: Diabetic Foot Ulcer Market Revenue and Forecast to 2030
11.1.1 Overview
11.1.1.1 Australia: Diabetic Foot Ulcer Market – Revenue and Forecast to 2030 (USD Million)
11.1.1.1.1 Australia: Diabetic Foot Ulcer Market, by Type, 2030 (USD Million)
11.1.1.1.2 Australia: Diabetic Foot Ulcer Market, by Treatment Type, 2030 (USD Million)
11.1.1.1.2.1 Australia: Diabetic Foot Ulcer Market, by Advanced Wound Care Dressings, 2030 (USD Million)
11.1.1.1.2.2 Australia: Diabetic Foot Ulcer Market, by Biologics, 2030 (USD Million)
11.1.1.1.2.3 Australia: Diabetic Foot Ulcer Market, by Therapy Device, 2030 (USD Million)
11.1.1.1.3 Australia: Diabetic Foot Ulcer Market, by Infection Severity, 2030 (USD Million)
11.1.1.1.4 Australia: Diabetic Foot Ulcer Market, by End User, 2030 (USD Million)
11.1.1.2 South Korea: Diabetic Foot Ulcer Market – Revenue and Forecast to 2030 (USD Million)
11.1.1.2.1 South Korea: Diabetic Foot Ulcer Market – Revenue and Forecast to 2030 (USD Million)
11.1.1.2.2 South Korea: Diabetic Foot Ulcer Market, by Type, 2030 (USD Million)
11.1.1.2.3 South Korea: Diabetic Foot Ulcer Market, by Treatment Type, 2030 (USD Million)
11.1.1.2.3.1 South Korea: Diabetic Foot Ulcer Market, by Advanced Wound Care Dressings, 2030 (USD Million)
11.1.1.2.3.2 South Korea: Diabetic Foot Ulcer Market, by Biologics, 2030 (USD Million)
11.1.1.2.3.3 South Korea: Diabetic Foot Ulcer Market, by Therapy Device, 2030 (USD Million)
11.1.1.2.4 South Korea: Diabetic Foot Ulcer Market, by Infection Severity, 2030 (USD Million)
11.1.1.2.5 South Korea: Diabetic Foot Ulcer Market, by End User, 2030 (USD Million)
12. Pre and Post COVID-19 Impact
12.1 Pre and Post COVID-19 Impact
13. Australia & South Korea Diabetic Foot Ulcer Market – Industry Landscape
13.1 Overview
13.2 Growth Strategies in the Australia & South Korea Diabetic Foot Ulcer Market
13.3 Inorganic Growth Strategies
13.3.1 Overview
13.4 Organic Growth Strategies
13.4.1 Overview
14. Company Profiles
14.1 Convatec Group Plc
14.1.1 Key Facts
14.1.2 Business Description
14.1.3 Products and Services
14.1.4 Financial Overview
14.1.5 SWOT Analysis
14.1.6 Key Developments
14.2 3M Co
14.2.1 Key Facts
14.2.2 Business Description
14.2.3 Products and Services
14.2.4 Financial Overview
14.2.5 SWOT Analysis
14.2.6 Key Developments
14.3 Coloplast AS
14.3.1 Key Facts
14.3.2 Business Description
14.3.3 Products and Services
14.3.4 Financial Overview
14.3.5 SWOT Analysis
14.3.6 Key Developments
14.4 Smith & Nephew Plc
14.4.1 Key Facts
14.4.2 Business Description
14.4.3 Products and Services
14.4.4 Financial Overview
14.4.5 SWOT Analysis
14.4.6 Key Developments
14.5 B. Braun SE
14.5.1 Key Facts
14.5.2 Business Description
14.5.3 Products and Services
14.5.4 Financial Overview
14.5.5 SWOT Analysis
14.5.6 Key Developments
14.6 Molnlycke Health Care AB
14.6.1 Key Facts
14.6.2 Business Description
14.6.3 Products and Services
14.6.4 Financial Overview
14.6.5 SWOT Analysis
14.6.6 Key Developments
14.7 MiMedx Group Inc
14.7.1 Key Facts
14.7.2 Business Description
14.7.3 Products and Services
14.7.4 Financial Overview
14.7.5 SWOT Analysis
14.7.6 Key Developments
14.8 URGO MEDICAL Australia Pty Ltd
14.8.1 Key Facts
14.8.2 Business Description
14.8.3 Products and Services
14.8.4 Financial Overview
14.8.5 SWOT Analysis
14.8.6 Key Developments
14.9 Medline Industries LP
14.9.1 Key Facts
14.9.2 Business Description
14.9.3 Products and Services
14.9.4 Financial Overview
14.9.5 SWOT Analysis
14.9.6 Key Developments
14.10 Organogenesis Inc.
14.10.1 Key Facts
14.10.2 Business Description
14.10.3 Products and Services
14.10.4 Financial Overview
14.10.5 SWOT Analysis
14.10.6 Key Developments
15. Appendix
15.1 About The Insight Partners
15.2 Glossary of Terms
List of Tables
Table 1. Australia & South Korea Diabetic Foot Ulcer Market Segmentation
Table 2. DUSS Scoring System
Table 3. Size (Area, Depth), Sepsis, Arteriopathy, Denervation System
Table 4. Australia: Diabetic Foot Ulcer Market, by Ulcer Type – Revenue and Forecast to 2030 (USD Million)
Table 5. Australia: Diabetic Foot Ulcer Market, by Treatment Type – Revenue and Forecast to 2030 (USD Million)
Table 6. Australia: Diabetic Foot Ulcer Market, by Advanced Wound Care Dressings – Revenue and Forecast to 2030 (USD Million)
Table 7. Australia: Diabetic Foot Ulcer Market, by Biologics– Revenue and Forecast to 2030 (USD Million)
Table 8. Australia: Diabetic Foot Ulcer Market, by Therapy Device– Revenue and Forecast to 2030 (USD Million)
Table 9. Australia: Diabetic Foot Ulcer Market, by Infection Severity – Revenue and Forecast to 2030 (USD Million)
Table 10. Australia: Diabetic Foot Ulcer Market, by End User – Revenue and Forecast to 2030 (USD Million)
Table 11. South Korea: Diabetic Foot Ulcer Market, by Type – Revenue and Forecast to 2030 (USD Million)
Table 12. South Korea: Diabetic Foot Ulcer Market, by Treatment Type – Revenue and Forecast to 2030 (USD Million)
Table 13. South Korea: Diabetic Foot Ulcer Market, by Advanced Wound Care Dressings – Revenue and Forecast to 2030 (USD Million)
Table 14. South Korea: Diabetic Foot Ulcer Market, by Biologics– Revenue and Forecast to 2030 (USD Million)
Table 15. South Korea: Diabetic Foot Ulcer Market, by Therapy Device– Revenue and Forecast to 2030 (USD Million)
Table 16. South Korea: Diabetic Foot Ulcer Market, by Infection Severity – Revenue and Forecast to 2030 (USD Million)
Table 17. South Korea: Diabetic Foot Ulcer Market, by End User – Revenue and Forecast to 2030 (USD Million)
Table 18. Recent Inorganic Growth Strategies in the Australia & South Korea Diabetic Foot Ulcer Market
Table 19. Recent Organic Growth Strategies in the Australia & South Korea Diabetic Foot Ulcer Market
Table 20. Glossary of Terms
List of Figures
Figure 1. Australia & South Korea: PEST Analysis
Figure 2. List of Vendors
Figure 3. Number of Hospitalizations for DFU in Australia & South Korea, 2022
Figure 4. Australia & South Korea Diabetic Foot Ulcer Market - Key Industry Dynamics
Figure 5. Impact Analysis of Drivers and Restraints
Figure 6. Australia & South Korea Diabetic Foot Ulcer Market – Revenue Forecast and Analysis – 2020–2030
Figure 7. Australia & South Korea Diabetic Foot Ulcer Market Revenue Share, by Treatment Type 2022 & 2030 (%)
Figure 8. Advanced Wound Care Dressings: Australia & South Korea Diabetic Foot Ulcer Market – Revenue and Forecast to 2030 (US$ Million)
Figure 9. Alginate Dressings: Australia & South Korea Diabetic Foot Ulcer Market – Revenue and Forecast to 2030 (US$ Million)
Figure 10. Hydrofiber Dressings: Australia & South Korea Diabetic Foot Ulcer Market – Revenue and Forecast to 2030 (US$ Million)
Figure 11. Foam Dressings: Australia & South Korea Diabetic Foot Ulcer Market – Revenue and Forecast to 2030 (US$ Million)
Figure 12. Collagen Dressing: Australia & South Korea Diabetic Foot Ulcer Market – Revenue and Forecast to 2030 (US$ Million)
Figure 13. Film Dressing: Australia & South Korea Diabetic Foot Ulcer Market – Revenue and Forecast to 2030 (US$ Million)
Figure 14. Other Dressing: Australia & South Korea Diabetic Foot Ulcer Market – Revenue and Forecast to 2030 (US$ Million)
Figure 15. Biologics: Australia & South Korea Diabetic Foot Ulcer Market – Revenue and Forecast to 2030 (US$ Million)
Figure 16. Growth Factors: Australia & South Korea Diabetic Foot Ulcer Market – Revenue and Forecast to 2030 (US$ Million)
Figure 17. Skin Graft: Australia & South Korea Diabetic Foot Ulcer Market – Revenue and Forecast to 2030 (US$ Million)
Figure 18. Therapy Device: Australia & South Korea Diabetic Foot Ulcer Market – Revenue and Forecast to 2030 (US$ Million)
Figure 19. Negative Pressure Wound Therapy: Australia & South Korea Diabetic Foot Ulcer Market – Revenue and Forecast to 2030 (US$ Million)
Figure 20. Ultrasound Therapy: Australia & South Korea Diabetic Foot Ulcer Market – Revenue and Forecast to 2030 (US$ Million)
Figure 21. Australia & South Korea Diabetic Foot Ulcer Market Revenue Share, By Ulcer Type 2022 & 2030 (%)
Figure 22. Neuropathic Ulcers: Australia & South Korea Diabetic Foot Ulcer Market – Revenue and Forecast to 2030 (US$ Million)
Figure 23. Ischemic Ulcers: Australia & South Korea Diabetic Foot Ulcer Market – Revenue and Forecast to 2030 (US$ Million)
Figure 24. Neuro-ischemic Ulcers: Australia & South Korea Diabetic Foot Ulcer Market – Revenue and Forecast to 2030 (US$ Million)
Figure 25. Australia & South Korea Diabetic Foot Ulcer Market Revenue Share, By Infection Severity 2022 & 2030 (%)
Figure 26. Mild: Australia & South Korea Diabetic Foot Ulcer Market – Revenue and Forecast to 2030 (US$ Million)
Figure 27. Moderate: Australia & South Korea Diabetic Foot Ulcer Market – Revenue and Forecast to 2030 (US$ Million)
Figure 28. Severe: Australia & South Korea Diabetic Foot Ulcer Market – Revenue and Forecast to 2030 (US$ Million)
Figure 29. Australia & South Korea Diabetic Foot Ulcer Market Revenue Share, By End User 2022 & 2030 (%)
Figure 30. Hospitals: Australia & South Korea Diabetic Foot Ulcer Market – Revenue and Forecast to 2030 (US$ Million)
Figure 31. Ambulatory Surgical Centers: Australia & South Korea Diabetic Foot Ulcer Market – Revenue and Forecast to 2030 (US$ Million)
Figure 32. Home Care: Australia & South Korea Diabetic Foot Ulcer Market – Revenue and Forecast to 2030 (US$ Million)
Figure 33. Australia: Diabetic Foot Ulcer Market – Revenue and Forecast to 2030 (USD Million)
Figure 34. South Korea: Diabetic Foot Ulcer Market – Revenue and Forecast to 2030 (USD Million)
Figure 35. Pre and Post COVID-19 Impact on Australia & South Korea Diabetic Foot Ulcer Market
Figure 36. Growth Strategies in the Australia & South Korea Diabetic Foot Ulcer Market
The List of Companies - Australia and South Korea Diabetic Foot Ulcer Market
- CONVATEC GROUP PLC
- 3M CO
- COLOPLAST A/S
- SMITH & NEPHEW PLC
- B. BRAUN SE
- MOLNLYCKE HEALTH CARE
- MIMEDX GROUP INC
- URGO MEDICAL AUSTRALIA PTY LTD
- MEDLINE INDUSTRIES LP
- ORGANOGENESIS INC
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Trends and growth analysis reports related to Australia & South Korea Diabetic Foot Ulcer Market
Sep 2023
Infectious Diasease Therapeutics Market
Size and Forecast (2020–2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Drug Class (Anti-viral, Anti Bacterial, Anti-Fungal, and Others), Indication (HIV, Hepatitis, Tuberculosis, Influenza, HPV, and Others), Route of Administration (Oral, Parenteral, Topical, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others), and Geography
Sep 2023
Clinic Casting and Splinting Products Market
Size and Forecast (2020–2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product [Casting (Casts, Tapes, Cutters, and Casting Accessories) and Splinting (Splints and Splinting Accessories)], Application (Acute Fractures or Sprains, Tendon and Ligament Injuries, and Others), Material (Plaster of Paris, Fiberglass, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Sep 2023
Myopia Treatment Market
Size and Forecast (2020–2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type (High Myopia, Degenerative Myopia, Progressive Myopia), Treatment [Low-Dose Atropine Eye Drops, Ortho-K, Contact Lenses, and Refractive Surgery (LASIK, PRK)], Age Group (Adult Myopia and Childhood Myopia), End User (Hospitals and Clinics, Specialty Clinics, and Refractive Surgery Centers), and Geography
Sep 2023
Epilepsy Market
Size and Forecast (2020–2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type (Progressive Myoclonic Epilepsy, Reflex Epilepsy, Generalized Epilepsy, and Other), Route of Administration (Oral, Parenteral, and Others), Treatment Type (First-Generation Drugs, Second-Generation Drugs, and Third-Generation Drugs), Age Group (Adults and Children), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others), and Geography
Sep 2023
Vaccine Adjuvants Market
Size and Forecast (2020–2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Adjuvant Class (Mineral Salt Adjuvant, Emulsion Adjuvant, Liposome Adjuvant, and Others), Type (Human Vaccine Adjuvant and Veterinary Vaccine Adjuvant), and Geography
Sep 2023
Human Vaccine Adjuvants Market
Size and Forecast (2020–2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type (Particulate Adjuvant, Emulsion Adjuvant, Combination Adjuvant, and Others), Application (Influenza, Hepatitis, Human papilloma virus (HPV), and Others), End User (Pharmaceutical and Biotechnology Companies, CMOs and CROs, and Others), and Geography
Sep 2023
Epilepsy Drugs Market
Size and Forecast (2020–2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Treatment (First-Generation Anti-Epileptics, Second Generation Anti-Epileptics, Third Generation Anti-Epileptics), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others), and Geography
Sep 2023
Aquatic Veterinary Market
Size and Forecast (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type (Diagnostics and Treatments), Species (Fish, Crustaceans, Mollusca, and Others), Disease Source (Bacteria, Viruses, Parasites, and Others), Route of Administration (Water Medication, Medicated Feed, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Get Free Sample For